Valliant John 4
4 · Fusion Pharmaceuticals Inc. · Filed Apr 27, 2022
Insider Transaction Report
Form 4
Valliant John
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2022-04-26$6.07/sh−2,147$13,032→ 322,658 total - Sale
Common Stock
2022-04-25$6.03/sh−2,036$12,277→ 324,805 total - Sale
Common Stock
2022-04-27$6.03/sh−4,511$27,201→ 318,147 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.00 to $6.09 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.00 to $6.17 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.00 to $6.24 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.